Cost-Effectiveness of Canakinumab From a Canadian Perspective for Recurrent Cardiovascular Events.

ABSTRACT:

Background

Cardiovascular (CV) disease is a condition with high levels of morbidity and mortality. Canakinumab is a novel monoclonal antibody therapy that has been shown to reduce CV events but is associated with side effects and high cost. The main objective for this analysis is to determine whether canakinumab use is cost-effective for the prevention of recurrent CV events.

Methods

A decision model was developed to estimate the direct costs and outcomes among patients who have suffered a myocardial infarction and are treated with canakinumab. A lifetime study horizon was used to analyze the base-case costs and utilities from the perspective of the Canadian publicly funded healthcare system. Markov modeling was used in combination with Monte Carlo simulation to derive expec

SUBMITTER: Boczar KE 

PROVIDER: S-EPMC9123368 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature